Ibuprofen and Alzheimer's disease.
Küçük Resim Yok
Tarih
2004
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
There is epidemiological observation that long-term treatment of patients suffering from rheumatoid arthritis with ibuprofen results in reduced risk and delayed onset of Alzheimer's disease (AD). Chronic central nervous system inflammation in AD brain is implicated in the pathology, but how ibuprofen impacts the pathogenic AD pathways is unclear. Ibuprofen, a commonly used over-the-counter nonsteroidal anti-inflammatory drug (NSAID) that is a cyclooxygenase (COX)-1 and COX-2 inhibitor as well as a peroxisome proliferator-activated receptor (PPAR) agonist, decreases the production of nitric oxide (NO), protects neurons against glutamate toxicity and decreases the production of proinflammatory cytokines. Ibuprofen crosses the blood brain barrier and suppresses neuritic plaque pathology and inflammation in AD brain. Furthermore, ibuprofen is a potent free radical scavenger, and it could reduce lipid peroxidation and free radical generation. Because of neuroprotective activity, relative safety, and its long history of use, ibuprofen is currently being developed for clinical use in AD. Ibuprofen may be a promising new therapeutic avenue for the treatment of neurodegenerative diseases such as AD.
Açıklama
Anahtar Kelimeler
Ibuprofen; Nonsteroid Antiinflammatory Agent; Alzheimer Disease; Drug Effect; Human; Immunology; Immunomodulation; Inflammation; Pathology; Review; Rheumatoid Arthritis; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Ibuprofen; Inflammation; Neuroimmunomodulation
Kaynak
Folia medica
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
46
Sayı
2
